AIMS: Global survival studies in cancer have generally shown favourable development, but studies over extended periods on populations for which medical care is essentially free of charge are lacking. METHODS: We analyse relative 1- and 5-year survival in all solid cancers in Denmark, Finland, Norway and Sweden through a 50-year period (1970-2019) using the NORDCAN database. RESULTS: The most recent survival results showed three types of patterns. Cancers of very good survival (5-year survival ∼90%) included common cancers of the breast and prostate, as well as melanoma. The second pattern, which included the largest number of cancers, showed 1-year survival of over 80% and a drop of 10-20 % units in 5-year survival. The third group consisted of eight fatal cancers, sharing poor 5-year survival (around 20%). The 50-year improvement in 1-year survival was largest (30-50 % units) in kidney, brain, gallbladder and liver cancers, and (∼30%) in colon, small intestinal, lung, pleural, pancreas and ovarian cancers. Improvements in 5-year survival were highest (40-50 % units) in prostate and kidney cancers but remained at 10-20 % units for the eight fatal cancers. Survival showed significant sex preferences for a few cancers. CONCLUSIONS: The analysis over a half-century confirms the progress in 'real-world' cancer control, and in 84% of patients 5-year survival was >60%. Metastases remain a challenge, placing the emphasis on early detection before metastasis occurs. Novel therapies, such as immunotherapy which has curative potential even against metastatic disease, are needed.

Biomedical Center Faculty of Medicine and Biomedical Center in Pilsen Charles University Prague 30605 Pilsen Czech Republic

Biomedical Center Faculty of Medicine and Biomedical Center in Pilsen Charles University Prague 30605 Pilsen Czech Republic; Division of Cancer Epidemiology German Cancer Research Center Im Neuenheimer Feld 580 D 69120 Heidelberg Germany

Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Finland; Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

Hopp Children's Cancer Center Heidelberg Germany

Komentář v

Eur J Cancer. 2023 Apr;183:190. doi: 10.1016/j.ejca.2023.01.012. PubMed

Komentář v

Eur J Cancer. 2023 Apr;183:188-189. doi: 10.1016/j.ejca.2022.12.033. PubMed

Citace poskytuje Crossref.org

Survival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients

Survival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countries

Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis

Survival in oral and pharyngeal cancers is catching up with laryngeal cancer in the NORDIC countries through a half century

Conditional survival in breast cancer up to 10 years in the Nordic countries

Long-Term Periodic and Conditional Survival Trends in Prostate, Testicular, and Penile Cancers in the Nordic Countries, Marking Timing of Improvements

Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements

Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries

Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers

Survival in melanoma in the nordic countries into the era of targeted and immunological therapies

Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century

Survival in Lung Cancer in the Nordic Countries Through A Half Century

Survival in gastric and esophageal cancers in the Nordic countries through a half century

Incidence, Mortality and Survival Trends in Breast Cancers Coincident with Introduction of Mammography in the Nordic Countries